Biblio

Author Title [ Type

] Year

Filters: Author is Ayuk, Francis [Clear All Filters]

Journal Article

Radujkovic A, Dietrich S, Blok H-J, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, et al. Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party. Biol Blood Marrow Transplant. 2019.

Daghia G, Zabelina T, Zeck G, von Pein U-M, Christopeit M, Wolschke C, Ayuk F, Kröger N. Allogeneic stem cell transplantation for myelofibrosis patients aged ≥ 65 years. Eur J Haematol. 2019.

Novak P, Zabelina T, Wolschke C, Ayuk F, Christopeit M, Kröger N. Allogeneic Stem Cell Transplantation for patients with lower risk MDS. Biol Blood Marrow Transplant. 2020.

Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, et al. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med. 2016;374(1):43-53.

Gagelmann N, Ayuk F, Atanackovic D, Kröger N. B cell maturation antigen-specific CAR T cells for relapsed or refractory multiple myeloma: a meta-analysis. Eur J Haematol. 2019.

von Felden J, Alric L, Pischke S, Aitken C, Schlabe S, Spengler U, Giordani MTeresa, Schnitzler P, Bettinger D, Thimme R, et al. The Burden of Hepatitis E among Patients with Hematological Malignancies: a Retrospective European Cohort Study. J Hepatol. 2019.

Klyuchnikov E, Badbaran A, Massoud R, Fritsche-Friedland U, Janson D, Ayuk F, Wolschke C, Bacher U, Kröger N. Enhanced immune reconstitution of γδ T cells after allograft overcomes negative impact of pre-transplant MRD positive status in AML patients.: γδ T cells and MRD+ AML. Transplant Cell Ther. 2021.

Zewde MGetachew, Morales G, Gandhi I, Özbek U, Aguayo-Hiraldo P, Ayuk F, Baez J, Chanswangphuwana C, Choe H, DeFilipp Z, et al. Evaluation of elafin as a prognostic biomarker in acute graft-versus-host disease. Transplant Cell Ther. 2021.

Bethge WAndreas, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner-Drouet EMaria, Wulf GG, Marks R, et al. GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. Blood. 2022.

Horvatits T, Wißmann J-E, Johne R, Groschup MH, Gadicherla AK, Wiesch JSchulze Zu, Eiden M, Todt D, Reimer R, Dähnert L, et al. Hepatitis E virus persists in the ejaculate of chronically infected men. J Hepatol. 2021.

Atagunduz IKaygusuz, Christopeit M, Ayuk F, Zeck G, Wolschke C, Kröger N. Incidence and Outcome of Late Relapse after Allogeneic Stem Cell Transplantation for Myelofibrosis. Biol Blood Marrow Transplant. 2020.

Klyuchnikov E, Langebrake C, Badbaran A, Dadkhah A, Massoud R, Freiberger P, Ayuk F, Janson D, Wolschke C, Bacher U, et al. Individualized busulfan dosing improves outcomes compared to fixed dose administration in pre-transplant MRD positive AML patients with intermediate risk undergoing allogeneic stem cell transplantation in CR. Eur J Haematol. 2022.

Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, Chanswangphuwana C, Efebera YA, Holler E, Litzow M, et al. International, multi-center standardization of acute graft-versus-host disease clinical data collection: a report from the MAGIC consortium. Biol Blood Marrow Transplant. 2015.

Essmann S, Heestermans M, Dadkhah A, Janson D, Wolschke C, Ayuk F, Kröger NM, Langebrake C. Iron Chelation with Deferasirox suppresses the Appearance of LPI during Conditioning Chemotherapy prior to Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2022.

Srinagesh HK, Özbek U, Kapoor U, Ayuk F, Aziz M, Ben-David K, Choe HK, DeFilipp Z, Etra A, Grupp SA, et al. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv. 2019;3(23):4034-4042.

Pidala J, Kitko C, Lee SJ, Carpenter P, Cuvelier GDE, Holtan S, Flowers MED, Cutler C, Jagasia M, Gooley T, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transplant Cell Ther. 2021.

Robin M, Porcher R, Wolschke C, de Fontbrune FSicre, Alchalby H, Christopeit M, Cassinat B, Zabelina T, de Latour RPeffault, Ayuk F, et al. Outcome after transplantation according to reduced intensity conditioning regimen in patients transplanted for myelofibrosis. Biol Blood Marrow Transplant. 2016.

Schieferdecker A, Shoshani O, Westner B, Zipori D, Fehse B, Kröger N, Ayuk F. Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins. Oncotarget. 2016.

Gagelmann N, Wolschke C, Salit RB, Schroeder T, Ditschkowski M, Panagiota V, Cassinat B, Thol F, Badbaran A, Robin M, et al. Reduced intensity hematopoietic stem cell transplantation for myelofibrosis in accelerated-phase. Blood Adv. 2022.

Frick M, Chan W, Arends CMaximilian, Hablesreiter R, Halik A, Heuser M, Michonneau D, Blau O, Hoyer K, Christen F, et al. Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2018:JCO2018792184.

Modemann F, Ayuk F, Wolschke C, Christopeit M, Janson D, von Pein U-M, Kröger N. Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level. Bone Marrow Transplant. 2020.

Nitsch E, Mina S, Brammer I, Pace A, Schuch G, Bokemeyer C, Zander A, Kröger N, Ayuk F. Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines. Anticancer Res. 2014;34(4):1779-84.